Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

This publication has 70 references indexed in Scilit:

• Development of a Genotype 325–Specific proCPU/TAFI ELISA
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2003
• Human Procarboxypeptidase B: Three-dimensional Structure and Implications for Thrombin-activatable Fibrinolysis Inhibitor (TAFI)
  Journal of Molecular Biology, 2002
• Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms
  Human Genetics, 2001
• Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties
  Published by Elsevier ,1998
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex
  Published by Elsevier ,1996
• Activated Human Plasma Carboxypeptidase B Is Retained in the Blood by Binding to α2-Macroglobulin and Pregnancy Zone Protein
  Journal of Biological Chemistry, 1996
• Activation and Characterization of Procarboxypeptidase B from Human Plasma
  Biochemistry, 1995
• Dental surgery in patients with severe factor XI deficiency without plasma replacement
  Blood Coagulation & Fibrinolysis, 1992
• An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits
  Biochemical and Biophysical Research Communications, 1989
• C‐terminal lysine residues of fibrinogen fragments essential for binding to plasminogen
  FEBS Letters, 1985